Teresa Petrella, MD, MHSc, FRCPC, discusses long-term data that inform the sequencing of immunotherapy and targeted therapies for frontline melanoma.
Of Interest
Cost-of-Care Discussions Between Cancer Patients & Providers
Most physicians agree that patients should know how much they’re going to pay for treatment before deciding on a plan. According to a survey of breast cancer surgeons, 87 percent agreed with this. Yet, it’s only a minority of physicians who claim they have cost-of-care discussions with their patients.
AI diagnostic platform improves early detection of skin cancer
If detected early, the prognosis for skin cancer is excellent. An innovative full-body scanner linked to an AI diagnostic platform is set to help with early detection of melanoma. In just six minutes, it automatically scans a patient’s entire body, providing a risk assessment for each anomalous change found in the skin.
1 in 5 Patients Experience Skin Toxicity With Nivolumab/Relatlimab
In a study of patients with advanced melanoma, the prevalence of cutaneous immune–related adverse events (cirAEs) associated with nivolumab/relatlimab combination therapy was 21.5%, with rash and maculopapular eruption being most common.